doi: 10.2337/dc23-S009 [DOI] [PMC free article] [PubMed] [Google Scholar] 9
Foundational research is available through PubMed (pubmed.ncbi.nlm.nih.gov) and the National Institutes of Healths PMC database (pmc.ncbi.nlm.nih.gov), where researchers can access peer-reviewed studies on CJC-1295, the DAC modification platform, and GHRH analog research
A 2023 market analysis showed that compounded GLP-1 options cost 40-60% less than brand-name alternatives while maintaining the same efficacy and safety standards when sourced from accredited compounding facilities
Mild nausea, appetite suppression, and injection-site tenderness are expected
The incidence rate of diarrhea in patients who receive tirzepatide was 16.24%, while the rate in the comparators was 8.63%, and it was significantly higher in the tirzepatide arm than in the comparators (RR, 2.07
While this risk has not been confirmed in human epidemiological studies, patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use orforglipron or any GLP-1 receptor agonist